Regeneron Pharmaceuticals, Inc.announced the first presentation of positive results from the Phase 3 QUASAR trial investigating EYLEA HD® (afliber...
Eli Lilly and Company announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely acti...
AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam), as the first and only fixed-...
Merck known as MSD outside of the United States and Canada, announced the initiation of waveLINE-010, a pivotal Phase 3 clinical trial evaluating ziloverta...
Genentech, a member of the Roche Group, announced that a detailed analysis of its Phase III REGENCY trial of Gazyva® (obinutuzumab) in people with acti...
Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company announced that the New England Journal of Medicine (NEJ...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce the completion of patient enrollment in the global Phase III clini...
AstraZeneca’s Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of adults ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/...
-Medidata, a Dassault Systèmes brand, reaffirms its vision and commitment to advancing the life sciences industry and transforming patient experie...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) announced an exclusive, global license agreement ...
PhaseV, a pioneer in software and machine learning (ML) for clinical trial optimization, announced it has entered a strategic partnership with&...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...
Bristol Myers Squibb (NYSE: BMY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...
© 2025 Biopharma Boardroom. All Rights Reserved.
